Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Surgical Treatment of Cushing's Disease: The Lessons Learned.

Advances and technical standards in neurosurgery·2025

Same author

Driving performance of long-term users of sedating antidepressants and benzodiazepines.

Traffic injury prevention·2024

Same author

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study.

Brain, behavior, and immunity·2023

Same author

Journal of psychopharmacology (Oxford, England)·2023

Same author

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis.

Psychopharmacology·2022

Same author

The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.

Psychopharmacology·2022

Same journal

Shared genetic architecture between psychiatric and insulin-related traits in the general population.

Neuroscience applied·2026

Same journal

Bipolar disorder and somatic diseases: Focus on oxidative stress markers.

Neuroscience applied·2026

Same journal

Clinical trials in neurosciences: Need for standards for innovation on clinical outcomes.

Neuroscience applied·2026

Same journal

Involvement of persons with lived experience in mental health research: recommendations.

Neuroscience applied·2026

Same journal

Olfactory impairment in Huntington's disease: A systematic review and meta-analysis.

Neuroscience applied·2026

Same journal

Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.

Neuroscience applied·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 15, 2025

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections

Published on: November 8, 2024

Harnessing brain-derived extracellular vesicles to support RDoC-based drug development.

I Magaraggia^1,2,3, J Krauskopf¹, J G Ramaekers²

¹Department of Toxicogenomics, Faculty of Health, Medicine and Life Science, Maastricht University, P.O. 616, 6200, Maastricht, the Netherlands.

Neuroscience Applied

|July 14, 2025

Summary

This summary is machine-generated.

Brain-derived extracellular vesicles (BDEVs) show promise as non-invasive biomarkers for Research Domain Criteria (RDoC)-based drug discovery. Their cargo, especially miRNA, can reveal molecular mechanisms of CNS drug effects.

More Related Videos

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

Formulating and Characterizing an Exosome-based Dopamine Carrier System

Formulating and Characterizing an Exosome-based Dopamine Carrier System

Published on: April 4, 2022

Related Experiment Videos

Last Updated: Sep 15, 2025

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections

Published on: November 8, 2024

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

Formulating and Characterizing an Exosome-based Dopamine Carrier System

Formulating and Characterizing an Exosome-based Dopamine Carrier System

Published on: April 4, 2022

Area of Science:

Neuroscience
Biomarker Discovery
Pharmacology

Background:

The Research Domain Criteria (RDoC) framework aids neuropsychiatric disorder research but lacks molecular biomarkers.
Integrating cellular and molecular brain processes into RDoC is challenging due to insufficient biomarkers.

Purpose of the Study:

To explore brain-derived extracellular vesicles (BDEVs) as non-invasive mechanistic biomarkers for RDoC-based drug discovery.
To highlight the potential of BDEV cargo, particularly miRNA, in understanding CNS drug mechanisms.

Main Methods:

Review of BDEV classification, functions, isolation, and characterization techniques.
Analysis of studies investigating BDEV cargo in CNS drug discovery, focusing on target engagement, response, and toxicity.
Emphasis on miRNA within BDEVs as stable molecular readouts reflecting brain function.

Main Results:

BDEVs offer a source of non-invasive mechanistic biomarkers for RDoC-based drug discovery.
BDEV cargo, especially miRNA, can provide insights into drug effects on brain function.
miRNA cargo is stable and reflects dynamic changes, aiding in target engagement and toxicity assessment.

Conclusions:

BDEVs, particularly their miRNA cargo, are a promising tool for advancing RDoC-based CNS drug discovery.
Further investigation and validation of BDEV miRNA cargo are needed to overcome current challenges.
BDEVs can bridge the gap between cellular processes and RDoC framework in drug development.